Walgreens Boots Alliance Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Tim Wentworth

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.003%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

CEO

Tim Wentworth (64 yo)

less than a year

Tenure

Mr. Timothy C. Wentworth, also known as Tim, served as Director of Ushur, Inc. since February 2022. He served as the Chief Executive Officer of Evernorth at Evernorth Health, Inc. (formerly known as Expres...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stefano Pessina	Executive Chairman of the Board	12.5yrs	US$7.57m	0.076% $ 6.1m
Manmohan Mahajan	Executive VP & Global CFO	1.3yrs	US$1.83m	0.019% $ 1.6m
Ornella Barra	Chief Operating Officer of International	no data	US$5.43m	0.24% $ 19.0m
Timothy Wentworth	CEO & Director	less than a year	geen gegevens	0.0026% $ 213.2k
Todd Heckman	Senior VP	1.3yrs	geen gegevens	0.00099% $ 79.9k
Neal Sample	Executive VP & Chief Information Officer	less than a year	geen gegevens	geen gegevens
Tiffany Kanaga	Vice President of Global Investor Relations	no data	geen gegevens	geen gegevens
Matthew D'Ambrosio	Senior VP and Global Chief Compliance & Ethics Officer	no data	geen gegevens	geen gegevens
Lanesha Minnix	Executive VP & Global Chief Legal Officer	less than a year	geen gegevens	geen gegevens
Elizabeth Burger	Executive VP & Chief Human Resources Officer	no data	geen gegevens	geen gegevens
Liyue Wu	Head of M&A - Asia	no data	geen gegevens	geen gegevens
Tracey Brown	Executive VP	2.9yrs	geen gegevens	0.0030% $ 243.1k

1.3yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0LSZ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stefano Pessina	Executive Chairman of the Board	12.5yrs	US$7.57m	0.076% $ 6.1m
Timothy Wentworth	CEO & Director	less than a year	geen gegevens	0.0026% $ 213.2k
Ginger Graham	Lead Independent Director	14.5yrs	US$366.85k	0.00025% $ 20.2k
Valerie Jarrett	Independent Director	4yrs	US$300.00k	0.00052% $ 42.0k
Nancy Schlichting	Independent Director	18yrs	US$319.97k	geen gegevens
John Lederer	Independent Director	9.5yrs	US$315.00k	0.0058% $ 466.8k
Bryan Hanson	Independent Director	2yrs	US$84.62k	0.0011% $ 90.4k
Janice Babiak	Independent Director	12.5yrs	US$325.00k	0.00014% $ 11.3k
William Shrank	Director	less than a year	geen gegevens	geen gegevens
Inderpal Bhandari	Independent Director	2.1yrs	US$115.29k	0.00035% $ 28.3k
Thomas Polen	Director	1.3yrs	US$14.13k	0.00020% $ 16.2k
Robert Huffines	Independent Director	less than a year	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0LSZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Walgreens Boots Alliance Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Walgreens Announces Executive Appointments

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Recent updates

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on December 12, 2024

Walgreens Boots Alliance, Inc. Expects to Close Approximately 1,200 Stores over the Next 3 Years with About 500 Targeted to Close in Fiscal 2025

Full year 2024 earnings released: US$10.01 loss per share (vs US$3.57 loss in FY 2023)

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2025

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Saxena White P.A. Files New Securities Fraud Class Action Lawsuit Against Walgreens Boots Alliance, Inc. and Certain of its Executives

Walgreens Boots Alliance, Inc. to Report Q4, 2024 Results on Oct 15, 2024

Walgreens Announces Executive Appointments

Upcoming dividend of US$0.25 per share

Gross Law Firm Announces Lawsuit Against Walgreens Boots Alliance, Inc

Third quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on September 12, 2024

Boots Chief Quits Reportedly After Walgreens' Sale Plan Stalls

Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.14 in 3Q 2023)

Walgreens Boots Alliance, Inc. to Report Q3, 2024 Results on Jun 27, 2024

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

Second quarter 2024 earnings released: US$6.85 loss per share (vs US$0.81 profit in 2Q 2023)

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought US$340k worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold US$661k worth of stock

Upcoming dividend of US$0.48 per share

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022